In lung cancer, PD‐1/PD‐L1 inhibitors have demonstrated superior response rates and survival outcomes compared to chemotherapy in patients with tumors expressing PD‐L1 in over 50% of cells [88]. Here, CD274 is linked to lung carcinoma.